KRAS and pancreatic neoplasm: In contrast, a peptidomimetic inhibitor of ADAM8 reduced tumour growth of pancreatic tumour cells in a xenograft model but was also able to impair tumour growth in a KRAS-driven pancreas cancer model and significantly prolonged overall survival [95].